Neuroone Medical Technologies (NMTC) Investor Update summary

Fiscal 2025 achievements and financial performance

• Achieved product revenues of $9.1 million, a 163% year-over-year increase, meeting guidance of $8–$10 million.

• Secured $3 million in license revenue from an expanded distribution agreement with Zimmer Biomet.

• Ended September 2025 with $6.6 million in cash and cash equivalents, with no debt on the balance sheet.

• Completed $8 million in financing from institutional investors and reduced operating expenses.

• Improved cost discipline and expect funding to last through at least fiscal 2026.

Strategic partnerships and technology roadmap

• Expanded agreement with Zimmer Biomet to include the OneRF ablation system for epilepsy and pain management.

• Maintained strategic relationships with Mayo Clinic and Zimmer Biomet, with interest from additional partners.

• Received first order from a large pharmaceutical firm for drug delivery device evaluation.

• Targeting partnerships for drug delivery and pain management platforms.

• Developing percutaneous spinal cord stimulation and basivertebral RF ablation systems for back pain.

Product launches and regulatory milestones

• Received early FDA clearance for the OneRF TN system for trigeminal neuralgia pain.

• Planning a limited launch of the OneRF TN system in November, with four centers lined up.

• Expecting around 10 cases for the new facial pain indication by year-end.

• Pursuing ISO 13485 clearance to expand revenue opportunities internationally.

• Initiating a OneRF registry to collect and publish patient outcomes data.